Skip to content Skip to footer
Subscribe Now
News

Avata Biosciences Enters a Co-Development and Licensing Deal with Oceanus Bio for AVAT-021 and AVAT-022 to Treat Epilepsy and Schizophrenia

Shots:Avata has entered into a co-development & licensing deal with Oceanus Bio for exclusive rights to AVAT-021 & AVAT-022 in Japan & Asia, excl. China & IndiaAs per the deal, Avata will receive $95M in co-development contributions, regulatory & sales milestones, plus double-digit royalties on sales, while Oceanus will lead regulatory activities &…
5 hours ago

Read more

News

AstraZeneca Partners with CSPC Pharmaceuticals to Identify and Develop Small Molecule Across Chronic Indications

Shots:AstraZeneca & CSPC have partnered to discover & develop pre-clinical candidates for multiple targets across chronic diseases, incl. a pre-clinical oral small molecule for immunological diseasesAs per the deal, CSPC will receive $110M upfront as well as ~$1.62B in development & ~$3.6B in sales milestones with net sales-based single digit royalties, while AstraZeneca…
2 days ago

Read more

Weekly Snapshot

PharmaShots Weekly Snapshots (Jun 09, 2025 – Jun 13, 2025)  

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar & Animal Health. Check out our full report below:  Apellis Pharmaceuticals and Sobi Report P-III (VALIANT) Trial Data of Empaveli for C3 Glomerulopathy (C3G) and Primary IC-MPGN Read More: Apellis Pharmaceuticals and Sobi Daiichi Sankyo Reports First Patient…
June 13, 2025

Read more

News

Philochem and RayzeBio Enter Into a Development and Commercialization Deal of ~$1.35B

Shots:Philochem and RayzeBio (BMS) entered into a development and commercialization agreement under which Philochem granted RayzeBio exclusive worldwide rights to develop, manufacture, and commercialize its radiopharmaceutical agent OncoACP3 for prostate cancer Under the agreement, Philochem will receive $350M up front and is eligible for up to $1B in development, regulatory, and commercial milestones, plus…
June 11, 2025

Read more

News

OS Therapies & EVERSANA Partner to Commercialize OST-HER2 in the US for Pediatric Osteosarcoma

Shots:OS Therapies joined hands with EVERSANA to commercialize OST-HER2 in the US for the treatment of pediatric lung metastatic osteosarcomaThis partnership leverages EVERSANA’s integrated commercialization platform, including market access, medical affairs, field deployment, patient services, and stakeholder engagement enabling OS Therapies to bring OST-HER2 to market rapidly and cost-effectivelyOS Therapies recently secured…
June 11, 2025

Read more

Aytu and Fabre-Kramer
News

Aytu BioPharma Collaborates with Fabre-Kramer Pharmaceuticals to Commercialize Exxua (Gepirone) in the US for Major Depressive Disorder

Shots:Aytu has collaborated with Fabre-Kramer to commercialize Exxua in the US for treating major depressive disorder; launch is expected in Q4’25As per the deal, Fabre-Kramer has received $3M upfront & is eligible to receive $3M within 45 days of the Exxua’s 1yr. commercial sale, increasing to $5M if net sales reach $35M as…
June 9, 2025

Read more

Cullinan and Genrix Bio
News

Cullinan Therapeutics Enters a ~$712M Licensing Deal with Genrix Bio for Velinotamig

Shots:Genrix Bio has granted Cullinan exclusive global license to velinotamig, excl. Greater China for all indications, with Cullinan planning to develop it in autoimmune diseasesAs per the deal, Genrix will receive $20M upfront, ~$292M in development & regulatory milestones & ~$400M in sales-based milestones, with net sales-based tiered royalties from mid-single digits up to…
June 5, 2025

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]